Securing the supply of benzathine penicillin: a global perspective on risks and mitigation strategies to prevent future shortages-Reference-Cited by-同舟云学术

Securing the supply of benzathine penicillin: a global perspective on risks and mitigation strategies to prevent future shortages

Published:2023-10-03 Issue: Volume: Page:
ISSN:1876-3413
Container-title:International Health
language:en
Short-container-title:

Author:

Seghers Frederic¹,Taylor Melanie M²^ORCID,Storey Andrew¹,Dong Jicui³,Wi Teodora C⁴,Wyber Rosemary⁵,Ralston Kate⁶,Nguimfack Boniface Dongmo⁴

Affiliation:

1. Clinton Health Access Initiative , 383 Dorchester Avenue, Boston, MA 02127 , USA

2. U.S. Centers for Disease Control and Prevention, Division of HIV Prevention 1600 , Clifton Road, Atlanta, GA 30333 , USA

3. World Health Organization, Regulation and Prequalification Department, Access to Medicines and Health Products Division. Avenue Appia 20 , 1211 Geneva 27 , Switzerland

4. World Health Organization, Communicable and Noncommunicable Diseases Division, Department of Global HIV, Hepatitis and STIs Programmes Avenue Appia 20 , 1211 Geneva 27 , Switzerland

5. Telethon Kids Institute, END RHD program, 15 Hospital Avenue , Nedlands, Western Australia 6009 , Australia

6. World Heart Federation , 32 Rue de Malatrex, Geneva 1201 , Switzerland

Abstract

Abstract Benzathine benzylpenicillin is a globally indispensable medicine. As a long-lasting injectable penicillin, it serves as the primary treatment for syphilis, group A streptococcal infections, rheumatic fever and rheumatic heart disease. A competitive market and low profit margins, compounded by limited visibility of demand, have resulted in a decreased number of active pharmaceutical ingredient (API) manufacturers. By 2016, only three Chinese API manufacturers remained, continuing to supply to the global market today. Recurring global shortages, a consequence of supply and demand imbalances, indicate underlying market risks. Therefore, the need for mitigation strategies is imperative.

Funder

Bill and Melinda Gates Foundation

Publisher

Oxford University Press (OUP)

Subject

Public Health, Environmental and Occupational Health,General Medicine,Health (social science)

Link

https://academic.oup.com/inthealth/advance-article-pdf/doi/10.1093/inthealth/ihad087/53957091/ihad087.pdf

Reference27 articles.

1. Evolution, evidence and effect of secondary prophylaxis against rheumatic fever;Wyber;J Pract Cardiovasc Scie,2015

2. Global burden of maternal and congenital syphilis and associated adverse birth outcomes—estimates for 2016 and progress since 2012;Korenromp;PLoS One,2019

3. Acute rheumatic fever and rheumatic heart disease;Carapetis;Nat Rev Dis Primers,2016

4. Global burden of cardiovascular diseases and risk factors, 1990–2019;Roth;J Am Coll Cardiol,2020